临床前CDMO研发筛选相关化合物如有产品调研服务, 请致函联系我们
客户展示
临床前CDMO研发化合物筛选
Clopidogrel (SR-25990C) Bisulfate
中文名称:硫酸氯吡格雷
CAS号:120202-66-6
分子式: C16H16ClNO2S.H2SO4 分子量: 419.90
产品形式: Bisulfate
研发状态: Not yet recruiting
研发用途: Atrial Fibrillation; Oral Anticoagulation; Stroke; Implant
研究机构: Javelin Medical; Population Health Research Institute
研发日期: January 20 2025
研发阶段: Not Applicable
Clopidogrel Bisulfate (SR-25990C, Clopidogrel hydrogen sulfate, Iscover, Plavix) is an oral, thienopyridine class antiplatelet agent.
Tofogliflozin(CSG 452)
中文名称:托格列净
CAS号:1201913-82-7
分子式: C22H26O6.H2O 分子量: 404.45
产品形式: hydrate
研发状态: Completed
研发用途: Healthy
研究机构: Kowa Research Institute Inc.
研发日期: February 24 2023
研发阶段: Phase 1
Tofogliflozin (CSG 452) is a novel sodium-glucose co-transporter 2(SGLT2) inhibitor with IC50 values of 2.9 nM and 8444 nM for hSGLT2 and hSGLT1, respectively.
Ixazomib Citrate (MLN9708) Analogue
中文名称:艾沙佐米柠檬酸盐
CAS号:1201902-80-8
分子式: C20H23BCl2N2O9 分子量: 517.12
产品形式: free base
研发状态: Withdrawn
研发用途: Neoplasms; Lymphoma
研究机构: Dartmouth-Hitchcock Medical Center
研发日期: Aug-16
研发阶段: Phase 1
Ixazomib Citrate (MLN9708) Analogue is the analogue of Ixazomib Citrate (MLN9708) from WO2016165677A1. Ixazomib Citrate (MLN9708) immediately hydrolyzed to Ixazomib (MLN2238), the biologically active form, on exposure to aqueous solutions or plasma. Ixazomib (MLN2238) inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Ixazomib (MLN2238) induces autophagy. Phase 3.
Duvelisib (IPI-145)
中文名称:(S)-3-(1-((9H-嘌呤-6-基)氨基)乙基)-8-氯-2-苯基-1(2H)-异喹啉酮
CAS号:1201438-56-3
分子式: C22H17ClN6O 分子量: 416.86
产品形式: free base
研发状态: Completed
研发用途: Healthy
研究机构: SecuraBio
研发日期: Nov-14
研发阶段: Phase 1
Duvelisib (IPI-145, INK1197) is a novel and selective PI3K δ/γ inhibitor with Ki and IC50 of 23 pM/243 pM and 1 nM/50 nM in cell-free assays, highly selective for PI3K δ/γ than other protein kinases. Phase 3.
(+)-α-Lipoic acid
中文名称:(R)-(+)-1,2-二硫戊环基-3-戊酸
CAS号:1200-22-2
分子式: C8H14O2S2 分子量: 206.33
产品形式: free base
研发状态: Recruiting
研发用途: Sepsis
研究机构: Ain Shams University
研发日期: March 10 2023
研发阶段: Phase 2 : Phase 3
(+)-α-Lipoic acid ((R)-(+)-α-Lipoic acid, α-Lipoic acid, Alpha-Lipoic acid), a physiological form of thioctic acid, is a strong antioxidant that relieves diabetic neuropathic symptoms. It shows superior antioxidative effects to its racemate. R(+)-α-lipoic acid is an essential cofactor of mitochondrial enzyme complexes. R(+)-α-lipoic acid inhibits NF-κB-dependent HIV-1 LTR activation.
Donepezil
中文名称:多萘哌齐碱
CAS号:120014-06-4
分子式: C24H29NO3 分子量: 379.49
产品形式: free base
研发状态: Not yet recruiting
研发用途: Alzheimer Disease
研究机构: Shanghai Synergy Pharmaceutical Sciences Co. Ltd.; Zhejiang Huahai Pharmaceutical Co. Ltd.
研发日期: June 1 2024
研发阶段: Phase 1
Donepezil (Aricept, Donepezilo) is a piperidine based, potent, specific, non-competitive and reversible inhibitor of acetylcholinesterase (AChE) used for the treatment of mild to moderate dementia of the Alzheimer's type.
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
